3Malkowicz SB.The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer.Urol Clin North Am,2000,27:63-73.
4Stampfer DS,Carpinito GA,Rodriguez-Vilianueva J,et al.Evaluation of NMP22 in the detection of transitional cell carcinoma of bladder.J Urol,1998,159:394-398.
5Sheinfeld J,Reuter VE,Melamed MR,et al.Enhanced bladder cancer detection with the lewis X antigen as a marker of neoplastic transformation.J Urol,1990,143:285-288.
6Pode D,Golijanin A,Sherman,et al.Immunostaining of Lewis X in cells from voided urine,cytopathology and ultrasound for noninvasive detection of bladder tumors.J Urol,1999,159:389-393.
7Zippe C,Pandrangi L,Agarwal A.NMP22 is a sensitive,cost-effective test in patients at risk for bladder cancer.J Urol,1999,161:62-65.
8Grocela JA,McDougal WS.Utility of nuclear matrix protein (NMP22) in the detecting bladder cancer.Urol Clin North Am,2001,27:47-51.
9Heicappell R,Wettig IC,Schostak M,et al.Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder.Eur Urol,1999,35:81-87.
10Burchardt M,Burchardt T,Shabsigh A,et al.Current concepts in biomarker technology for bladder cances.Clin Chem,2000,46:595-605.
二级参考文献11
1[1]Greider CW,Blackburn EH.Telomere,telomerase and cancer [J].Scientific Amer,1996,274(2):92-97.
2[2]Kazuhiro Y,Takashi S,Hidetoshi T,et al.Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cell in urine [J].Cancer,1997,79:362.
3[3]Elizabeth K,Jaime L,Yongli C,et al.Detection of bladder carcinoma cell in voided urine samples by assaying for the presence of telomerase activity [J].Cancer,1998,82:708.
4Mark SS,Joseph VB,Gennaro AC,et al.Use of a new tumor marker, urinary NMP 22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[].Journal d Urologie.1996
5Naoto M,Hideyuki A,Satoru I,et al.Clinical evaluation of nuclear matrix protein 22 (NMP 22) in urine as a novel marker for urothelial cancer[].European Urology.1997
6David SS,Gennaro AC,Julio RV,et al.Evaluation of NMP 22 in the detection of transitional cell carcinoma of the bladder[].Journal d Urologie.1998
7Craig Z,Lakshmi P,Ashok A.NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer[].Journal d Urologie.1999
8Marta SC,Enrique H,Julian M,et al.Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP 22 to detect bladder cancer[].Journal d Urologie.1999
9Alberto DN,Nicola E,Anna C,et al.Evaluation of urinary level of NMP 22 as a diagnostic marker for stage pTa-pT1 bladder cancer:comparison with urinary cytology and BTA test[].European Urology.1999
10Hughes JH,Katz RL,Rodriguez VJ,et al.Urinary nuclear matrix protein 22(NMP 22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder[].Diagnostic Cytopathology.1999
